Private Advisor Group LLC bought a new stake in CytomX Therapeutics Inc (NASDAQ:CTMX) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 165,231 shares of the biotechnology company’s stock, valued at approximately $3,843,000. Private Advisor Group LLC owned 0.42% of CytomX Therapeutics at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of the business. State of Wisconsin Investment Board raised its stake in CytomX Therapeutics by 87.1% in the second quarter. State of Wisconsin Investment Board now owns 39,300 shares of the biotechnology company’s stock valued at $898,000 after buying an additional 18,300 shares during the period. TD Asset Management Inc. raised its stake in CytomX Therapeutics by 8.5% in the second quarter. TD Asset Management Inc. now owns 47,200 shares of the biotechnology company’s stock valued at $1,079,000 after buying an additional 3,700 shares during the period. Federated Investors Inc. PA raised its stake in CytomX Therapeutics by 81.6% in the first quarter. Federated Investors Inc. PA now owns 125,932 shares of the biotechnology company’s stock valued at $3,583,000 after buying an additional 56,582 shares during the period. State Board of Administration of Florida Retirement System raised its stake in CytomX Therapeutics by 28.8% in the first quarter. State Board of Administration of Florida Retirement System now owns 12,706 shares of the biotechnology company’s stock valued at $361,000 after buying an additional 2,840 shares during the period. Finally, JBF Capital Inc. bought a new stake in CytomX Therapeutics in the first quarter valued at approximately $692,000. 72.17% of the stock is owned by hedge funds and other institutional investors.

CTMX has been the topic of several research analyst reports. ValuEngine lowered CytomX Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, August 29th. Zacks Investment Research raised CytomX Therapeutics from a “hold” rating to a “buy” rating and set a $28.00 price target on the stock in a research report on Tuesday, July 10th. BidaskClub downgraded CytomX Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, August 15th. SunTrust Banks started coverage on CytomX Therapeutics in a research report on Friday, June 1st. They set a “buy” rating and a $38.00 price target on the stock. Finally, HC Wainwright started coverage on CytomX Therapeutics in a report on Thursday. They issued a “buy” rating and a $32.00 target price on the stock. One analyst has rated the stock with a sell rating, two have issued a hold rating and ten have assigned a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $37.67.

NASDAQ:CTMX traded down $0.69 during trading hours on Friday, hitting $18.82. 464,146 shares of the company were exchanged, compared to its average volume of 310,708. The firm has a market cap of $853.41 million, a P/E ratio of -16.22 and a beta of 0.81. CytomX Therapeutics Inc has a one year low of $16.26 and a one year high of $35.00.

CytomX Therapeutics (NASDAQ:CTMX) last announced its earnings results on Wednesday, August 8th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.34) by ($0.01). The company had revenue of $21.34 million for the quarter, compared to the consensus estimate of $16.48 million. CytomX Therapeutics had a negative return on equity of 74.84% and a negative net margin of 44.46%. equities analysts anticipate that CytomX Therapeutics Inc will post -1.5 earnings per share for the current fiscal year.

In other news, insider Sean A. Mccarthy sold 13,052 shares of the firm’s stock in a transaction dated Monday, July 2nd. The stock was sold at an average price of $23.42, for a total value of $305,677.84. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Sean A. Mccarthy sold 2,028 shares of the firm’s stock in a transaction dated Tuesday, July 3rd. The shares were sold at an average price of $25.09, for a total value of $50,882.52. Following the completion of the sale, the chief executive officer now owns 84,091 shares of the company’s stock, valued at $2,109,843.19. The disclosure for this sale can be found here. Over the last three months, insiders sold 41,629 shares of company stock valued at $967,572. Corporate insiders own 8.50% of the company’s stock.

About CytomX Therapeutics

CytomX Therapeutics, Inc operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 anti-cancer target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel tumor antigen; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target.

Read More: How Do You Calculate Return on Investment (ROI)?

Institutional Ownership by Quarter for CytomX Therapeutics (NASDAQ:CTMX)

Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.